Lymphoma

Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL 3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL
Nirav Shah • 15 Feb 2023
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL 3:02
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Shah • 15 Feb 2023
The importance of managing hematologic toxicity associated with CAR-T therapy 2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe • 10 Feb 2023
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy 5:36
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy
Veit Buecklein • 9 Dec 2022
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL 1:23
CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL
Constantine Tam • 12 Dec 2022
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL 3:58
Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL
Jakub Svoboda • 11 Dec 2022
Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma 1:00
Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma
Mazyar Shadman • 9 Dec 2022
LMY-920 in non-Hodgkin lymphoma 1:58
LMY-920 in non-Hodgkin lymphoma
Jeff Liter • 27 Jan 2022
Mechanisms of resistance to CAR T-cell therapies 5:09
Mechanisms of resistance to CAR T-cell therapies
John Rossi • 26 Aug 2021
Chimeric engulfment receptor (CER) T-cell therapy 4:24
Chimeric engulfment receptor (CER) T-cell therapy
John Rossi • 26 Jul 2021
Liquid vs solid tumor strategies in cell therapy 2:17
Liquid vs solid tumor strategies in cell therapy
Kanya Rajangam • 13 Oct 2021
NKX019 in B-cell malignancies 1:05
NKX019 in B-cell malignancies
Kanya Rajangam • 13 Oct 2021
ISCT 2021 highlights: therapeutic deception, global regulation & CAR-T 4:33
ISCT 2021 highlights: therapeutic deception, global regulation & CAR-T
Aaron Levine • 28 May 2021
Challenges of CAR T-cell therapy for AML: is CD38 the answer? 6:10
Challenges of CAR T-cell therapy for AML: is CD38 the answer?
Lei Yu • 3 Jun 2021
Horizon scanning in anti-CD19 CAR T-cell therapy 3:07
Horizon scanning in anti-CD19 CAR T-cell therapy
Marco Alessandrini • 20 May 2021
Improving education in cell therapy 1:33
Improving education in cell therapy
Emanuele Ostuni • 12 Apr 2021
The content of VJRegenMed is intended for healthcare professionals